Sun Pharma Advanced Research Company Limited



Regd Office: Plot No. 5 & 6/1, Savli, G. I.D.C. Estate, Savli - Vadodara Highway, Manjusar Vadodara – 391 775. Tel.: +91-2667 666800 CIN: L73100GJ2006PLC047837. Website: www.sparc.life

Statement of Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2020

` in Lakhs

	Quarter ended			Half Year ended		Year ended
Particulars	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		(Refer Note 5)				
Revenue from operations	1,764	18,545	1,719	20,309	3,451	7,682
Other income	282	66	226	348	593	976
Total income	2,046	18,611	1,945	20,657	4,044	8,658
Expenses	_,,,,,		1,010		.,	-,
Cost of materials consumed	417	624	439	1,041	1,453	2,392
Employee benefits expense	2,283	2,400	2,328	4,683	4,595	9,309
Clinical trial expenses / products development expense	5,680	6,289	3,189	11,969	7,606	16,930
Professional charges	926	1,649	714	2,575	1,639	4,191
Finance costs	116	197	25	313	84	267
Depreciation and amortisation expense	278	278	225	556	450	948
License and fees	9	783	495	792	2,307	2,398
Other expenses	686	722	846	1,408	1,645	3,463
Total expenses	10,395	12,942	8,261	23,337	19,779	39,898
Profit / (loss) before tax	(8,349)	5,669	(6,316)	(2,680)	(15,735)	(31,240)
Tax expense	-	-	-	-	-	-
Profit / (loss) for the period	(8,349)	5,669	(6,316)	(2,680)	(15,735)	(31,240)
Other comprehensive income (OCI)						
Items that will not be reclassified to profit and loss (net actuarial gain / (loss) on	(65)	(66)	20	(131)	40	(247
Total comprehensive income / (loss) for the period	(8,414)	5,603	(6,296)	(2,811)	(15,695)	(31,487
Paid-up equity share capital (Face value `1 each)	2,621	2,621	2,621	2,621	2,621	2,621
Other equity						(4,485)
Basic and diluted earnings per share of `1 each	(3.19)	2.16	(2.41)	(1.02)	(6.00)	(11.92)
	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	,
See accompanying notes to the unaudited financial results						

Notes:

- 1 The above unaudited financial results have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and have been taken on record by the Board of Directors at its meeting held on November 9, 2020 after being reviewed by the Audit Committee and have been subjected to a limited review by Statutory Auditors of the Company.
- 2 The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.
- 3 The Company has a negative net worth as at September 30, 2020 and the current liabilities exceed current assets. The Company, as per business plans, is in the process of evaluating various sources of raising funds for its operations. The Company has also received a financial support letter from its parent company which is valid till time the Company is able to raise funds from external sources.
- 4 Since the beginning of 2020 until now, the global wide spread of COVID-19 is a fluid and challenging situation facing all the industries. The Company has taken all possible effective measures to limit and keep the impact of COVID-19 under control in order to ensure business continuity with minimal disruption. The Company has considered internal and external information while finalizing various estimates in relation to its financial results captions upto the date of approval of the financial results by the Board of Directors.
 - The Company will continue to pay close attention to the development of COVID-19, and will further evaluate and actively respond to such impact on the financial position and financial performance of the Company.
- The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are notified.
- 6 Previous period figures have been regrouped / rearranged, wherever necessary, to correspond to current period's presentation.

By order of the Board

Dilip S. Shanghvi Chairman and Managing Director

Mumbai, November 9, 2020

Sun Pharma Advanced Research Company Limited



Regd Office: Plot No. 5 & 6/1, Savli, G. I.D.C. Estate, Savli - Vadodara Highway, Manjusar Vadodara – 391 775. Tel. : +91-2667 666800 CIN: L73100GJ2006PLC047837. Website: www.sparc.life

Statement of Unaudited Assets and Liabilities as at September 30, 2020

			` in Lakhs
Particula	ars	As at 30.09.2020 Unaudited	As at 31.03.2020 Audited
ASSETS			
(A) Non-	-current assets		
(a)	Property, plant and equipment	9,856	10,299
(b)	Capital work-in-progress	590	35
(c)	Other intangible assets	77	88
(d)	Intangible assets under development	-	2,849
(e)	Financial assets		
	(i) Loans	7	,
(f)	Deferred tax assets (Net)	-	
(g)	Income tax assets (Net)	7,535	6,77
(h)	Other non-current assets	100	17:
` ,	Il non-current assets (A)	18,165	20,537
(D) 0			
. ,	rent assets		1
(a)	Financial assets	0.400	0.44
	(i) Investments	2,496	849
	(ii) Trade receivables	1,476	1,605
	(iii) Cash and cash equivalents	80	35
	(iv) Bank balance other than cash and cash equivalents	1	1
	(v) Loans	25	77
	(vi) Other financial assets	338	
(b)	Other current assets	2,413	4,142
	rrent assets (B)	6,829	6,719
TOTAL A	ASSETS	24,994	27,256
EQUITY	AND LIABILITIES		
Equity			
(a)	Equity share capital	2,621	2,62
(b)	Other equity	(7,295)	(4,48
Total eq	uity	(4,674)	(1,864
Liabilitie	es .		
(A) Non-	-current liabilities		
(a)	Financial liabilities		
()	(i) Borrowings	504	638
(b)	Other liabilities	3,924	3,924
(c)	Provisions	1,034	1,023
	n-current liabilities (A)	5,462	5,58
(B) Curr	ent liabilities		
(a)	Financial liabilities		
	(i) Borrowings	10,089	6,000
	(ii) Trade payables		
	(a) Total outstanding dues of micro and small enterprises	-	
	(b) Total outstanding dues of creditors other than micro and small enterprises	12,712	15,883
	(iii) Other financial liabilities	503	459
(b)	Other current liabilities	364	66
(c)	Provisions	538	53
Total cu	rrent liabilities (B)	24,206	23,53
Total lial	bilities	29,668	29,12
TOTAL E	EQUITY AND LIABILITIES	24,994	27,256

^{*} Includes ` 11,000 of security deposit considered good.

Sun Pharma Advanced Research Company Limited



Regd Office: Plot No. 5 & 6/1, Savli, G. I.D.C. Estate, Savli - Vadodara Highway, Manjusar Vadodara – 391 775. Tel. : +91-2667 666800 CIN : L73100GJ2006PLC047837. Website : www.sparc.life

Statement of Unaudited Cash Flow for the Half Year Ended September 30, 2020

`in Lakhs

starticulars ended a good good good good good good good g			` in Lakh
A Cash How from operating activities (2,679) (15,77 Adjustments for: Depreciation and amoritisation expense 190 Net Gain on sale of financial assets measured at fair value through profit or loss Net Gain anise on financial assets measured at fair value through profit or loss Net Gain anise on financial assets measured at fair value through profit or loss Net Gain anise on financial assets measured at fair value through profit or loss Net Gain anise on financial assets measured at fair value through profit or loss Net Gain anise on financial assets measured at fair value through profit or loss Net Gain anise on financial assets measured at fair value through profit or loss Net Gain anise on financial assets measured at fair value through profit or loss Net Gain account of adoption of Ind AS 115 (36) (36) (36) (37) (38	Particulars	ended 30.09.2020	30.09.2019
Case before tax		Unaudited	Unaudited
Adjustments for: Depreciation and amortisation expense Depreciation and amortisation expense Portition salewhole off property, plant and equipment and inlangible assets (net) Finance costs Interest income Net Gain on sale of financial assets measured at fair value through profit or loss Net Gain on sale on financial assets measured at fair value through profit or loss Net Gain arising on financial assets measured at fair value through profit or loss (3) (3) Impact on account of adoption of Ind AS 115 Very Claim arising of the sale of the sale of the value of through the sale of the value of the sale of the value of the sale of the sal	· · ·	(0.070)	45.70
Depreciation and amoritisation expense 556 4	Loss before tax	(2,679)	(15,735
Depreciation and amoritisation expense 556 4	Adjustments for:		
Profit on sale/winte off of property, plant and equipment and intangible assets (net) Finance costs 313 Interest income 314 Interest income 315 Interest incom	•	556	450
Finance costs 313	·		(2
Interest income Mot Coain on sale of financial assets measured at fair value through profit or loss Mot Coain on sale of financial assets measured at fair value through profit or loss Mot Coain on sale of financial assets measured at fair value through profit or loss Mot Coain on account of adoption of Ind AS 115	Finance costs	, ,	8
Set Sain on saile of financial assets measured at fair value through profit or loss 36 37 38 38 38 38 38 38 38	Interest income	#0	(-
Net Gain arising on financial assets measured at fair value thorugh profit or loss impact on account of adoption of Ind AS 115 1	Net Gain on sale of financial assets measured at fair value through profit or loss	(36)	(39
Impact on account of adoption of Ind AS 115 February Februar			(17
Net unrealised foreign exchange loss			`
Product development expense 2,849 1,045		61	9
		2,849	
Working capital adjustments: 132 (9 (Increase) / decrease in trade receivables 1,689 2 (Increase) / decrease) in trade payables (3,236) 2,3 Increase / (decrease) in other liabilities (326) (3 Increase / (decrease) in other liabilities (326) (3 Increase / (decrease) in provisions (809) (14,2 Cash used in operations (809) (14,2 Increase / (decrease) in rother liabilities (809) (14,2 Cash used in operations (809) (14,2 Increase / (decrease) in rother liabilities (809) (14,2 Increase / (decrease) in rother liabilities (809) (14,2 Increase / (decrease) in rother liabilities (809) (14,2 (Ash used in operations (809) (14,2 (Ash used in operations (809) (14,2 (Increase) (received in operations activities (297) (1,3 (Proceeds from sale (used in) purchase of investments (net) (1,858) 16,0 (Bank balances not considered as cash and cash equivalents 9 1			(15,68
(Increase) / decrease in trade receivables (Increase) / decrease in other assets 132 (9) (Increase) / (decrease) in trade payables 3,236 (2,4) Increase / (decrease) in trade payables (326) (3 (Increase) (recrease) in trade payables (326) (3 (Increase) (recrease) in trade payables (326) (3 (Increase) (recrease) in provisions (809) (14,2 (Increase) (recrease) in recreased (recrease) in r			, ,
(Increase) / decrease) in trade payables 1,689 2 Increase / (decrease) in trade payables (3,26) 2,4 Increase / (decrease) in provisions (36) (3 Increase / (decrease) in provisions (809) (14,2 Cash used in operations (809) (14,2 Income tax paid (net of refund) (763) (2 Net cash used in operating activities (A) (1,572) (14,5 B. Cash flow from investing activities (297) (1,3 Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets and evelopment) (297) (1,3 Proceeds from disposal of property, plant and equipment (1,8	Working capital adjustments:		
Increase (decrease) in trade payables (3,236) (2,4) (increase) (decrease) in other liabilities (326) (3) (326) (3) (326) (3) (326) ((Increase) / decrease in trade receivables	132	(97
Increase / (decrease) in other liabilities (326) (33 Increase) (decrease) in provisions (113) (2 Cash used in operations (809) (114,5 Cash used in operations (809) (114,5 Cash used in operations (11572) (14,5 Cash used in operating activities (A) (1,572) (1,3 Cash used in operating activities (A) (1,572)	(Increase) / decrease in other assets	1,689	28
Increase / (decrease) in provisions	Increase / (decrease) in trade payables	(3,236)	2,45
Cash used in operations (809) (14,2) Income tax paid (net of refund) (763) (2 Net cash used in operating activities (A) (1,572) (14,5 B. Cash flow from investing activities 8 Cash flow from investing activities (297) (1,3 Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets and intangible assets under development) 2 (1,3 Proceeds from disposal of property, plant and equipment (including capital work-in-progress, intangible assets and	Increase / (decrease) in other liabilities	(326)	(30
Income tax paid (net of refund)	Increase / (decrease) in provisions	(113)	(1
Net cash used in operating activities (A) B. Cash flow from investing activities Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets and edvelopment) Proceeds from disposal of property, plant and equipment Proceeds from disposal of property, plant and equipment Proceeds from sale/(used in) purchase of investments (net) Bank balances not considered as cash and cash equivalents Fixed deposits placed Fixed deposits placed Fixed deposits placed Poet cash (used in) / generated from investing activities (B) C. Cash flow from financing activities Proceeds from borrowings Proceeds from borr	Cash used in operations	(809)	(14,24
B. Cash flow from investing activities Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment Proceeds from sale/(used in) purchase of investments (net) Bank balances not considered as cash and cash equivalents Fixed deposits placed Fixed deposits matured Proceeds from investing activities (B) C. Cash flow from financing activities (B) C. Cash flow from financing activities Proceeds from borrowings (8,657) Interest paid Proceeds from financing activities (C) Proceds from financing activities (C) Proceeds from selection (C) Proceeds from financing activities (C) Proceed	Income tax paid (net of refund)	(763)	(29
Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment Proceeds from sale/(used in) purchase of investments (net) Bank balances not considered as cash and cash equivalents Fixed deposits placed Fixed deposits matured Interest received Net cash (used in) / generated from investing activities (B) C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* (as,657) (interest paid Net cash generated / (used in) from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents at the end for the period 80 (1,3 (1	Net cash used in operating activities (A)	(1,572)	(14,53
Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets under development) Proceeds from disposal of property, plant and equipment Proceeds from sale/(used in) purchase of investments (net) Bank balances not considered as cash and cash equivalents Fixed deposits placed Fixed deposits matured Interest received Net cash (used in) / generated from investing activities (B) C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* (as,657) (interest paid Net cash generated / (used in) from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents at the end for the period 80 (1,3 (1	B. Cash flow from investing activities		
assets under development) Proceeds from disposal of property, plant and equipment Proceeds from disposal of property, plant and equipment Proceeds from sale/(used in) purchase of investments (net) Bank balances not considered as cash and cash equivalents Fixed deposits placed Fixed deposits matured Proceeds from investing activities (B) C. Cash flow from financing activities (B) C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* Re-payment of borrowings* Re-payment of borrowings* Re-payment of borrowings (8,657) Ret increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents at the end for the period 80	•	(297)	(1,38
Proceeds from disposal of property, plant and equipment Proceeds from sale/(used in) purchase of investments (net) Bank balances not considered as cash and cash equivalents Fixed deposits placed Fixed deposits matured Fixed deposits matured Interest received Net cash (used in) / generated from investing activities (B) C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* Re-payment of borrowings* Re-payment of borrowings* Re-payment of borrowings (1990) Net cash generated / (used in) from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents at the end for the period 80		(==-,	(,,,,,
Proceeds from sale/(used in) purchase of investments (net) Bank balances not considered as cash and cash equivalents Fixed deposits placed Fixed deposits matured Interest received Net cash (used in) / generated from investing activities (B) C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* (190)		21	
Bank balances not considered as cash and cash equivalents Fixed deposits placed Fixed deposits matured Interest received Net cash (used in) / generated from investing activities (B) C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* Re-payment of borrowings* (190) (190) (Net cash generated / (used in) from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents at the end for the period Base of the proceed of the period o		(1.858)	16,09
Fixed deposits placed Fixed deposits matured Interest received Net cash (used in) / generated from investing activities (B) C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* Interest paid Net cash generated / (used in) from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents Cash and cash equivalents at the end for the period Re-payment of borrowings* (190) ((,,,,,,,	.,
Fixed deposits matured Interest received Net cash (used in) / generated from investing activities (B) C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* Interest paid Net cash generated / (used in) from financing activities (C) Net cash generated / (used in) from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents Cash and cash equivalents at the end for the period Recommendation of the period of the	·	_ !	
Interest received Net cash (used in) / generated from investing activities (B) C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* (8,657) (interest paid Net cash generated / (used in) from financing activities (C) Net cash generated / (used in) from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents Cash and cash equivalents at the end for the period 80		9	3
C. Cash flow from financing activities Proceeds from borrowings Re-payment of borrowings* (8,657) ((Interest paid (190)	Interest received	1	
Proceeds from borrowings Re-payment of borrowings* (Re-payment of borrowing	Net cash (used in) / generated from investing activities (B)	(2,124)	14,73
Proceeds from borrowings Re-payment of borrowings* (Re-payment of borrowing	C. Cash flow from financing activities		
Re-payment of borrowings* (8,657) (Interest paid (190) (190	Proceeds from borrowings	12,589	1
Interest paid Net cash generated / (used in) from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents Cash and cash equivalents at the end for the period Cash and cash equivalents at the end for the period 80	Re-payment of borrowings*	(8,657)	(6:
Net cash generated / (used in) from financing activities (C) Net increase in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents Cash and cash equivalents at the end for the period Cash and cash equivalents at the end for the period 80	Interest paid		(8)
Net increase in cash and cash equivalents (A+B+C) 46 Cash and cash equivalents at the beginning for the period 35 Effect of exchange differences on restatement of foreign currency cash and cash equivalents (1) Cash and cash equivalents at the end for the period 80	Net cash generated / (used in) from financing activities (C)	3,742	(14
Cash and cash equivalents at the beginning for the period Effect of exchange differences on restatement of foreign currency cash and cash equivalents Cash and cash equivalents at the end for the period 80	Net increase in cash and cash equivalents (A+B+C)		. 5
Effect of exchange differences on restatement of foreign currency cash and cash equivalents Cash and cash equivalents at the end for the period (1) 80	Cash and cash equivalents at the beginning for the period		3
Cash and cash equivalents at the end for the period 80	Effect of exchange differences on restatement of foreign currency cash and cash equivalents	(1)	
Includes payment of lease obligation	Cash and cash equivalents at the end for the period		9
	* Includes payment of lease obligation	•	